reports
- Kristof Samoy
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical Launches capital increase for indicative amount of € c....
Onward launches a capital increase for an indicative amount of € c.40m, including a € 22.5m cornerstone investment from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology. Euronext halts trading during the bookbuilding period to allow broader investor participation. Due to the transaction, we temporarily suspend coverage.
ONWARD® Medical lance une augmentation de capital d’un montant d’envir...
ONWARD® Medical lance une augmentation de capital d’un montant d’environ 40 millions d’euros dont 22,5 millions d’engagement ferme de la part d’Ottobock SE & Co. KGaA NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION OU LA DIFFUSION SERAIT ILLÉGALE. D'AUTRES RESTRICTIONS SONT APPLICABLES. VEUILLEZ CONSULTER L'AVIS IMPORTANT À LA FIN DU COMMUNIQUÉ DE PRESSE. CE COMMUNIQUÉ DE PRESSE CONTIENT DES INFORMATIONS PRIVÉES AU SENS DE L'ARTICLE (7)(1) DU RÈGLEMENT EUROPÉEN S...
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. ...
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) O...
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Wim Hoste
DSM-Firmenich Vitamin price recovery raises chances of successful ANH ...
A solid recovery of vitamin prices prompt us to raise our Animal Nutrition & Health (ANH) adjusted EBITDA forecasts for 2024-26 by 9-17% with our group forecasts over the period revised upwards by 1.5-3.9%. More importantly, we believe that the vitamin price recovery significantly increases the chances of a successful exit out of ANH with our exit price forecast increased from € 3.0-3.5bn to € 3.9-4.4bn, which corresponds to an EV/EBITDA25e multiple of 9-10x. We appreciate the core customer orie...
ONWARD® Medical Announces Changes to Board of Directors, Including Add...
ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman Ten Hoedt is a former Medtronic President and Executive Committee Member; also a former Chairman of MedTech Europe Commercial and digital health expert Rahma Samow will also join as Director Current Board Chairman Jan Ohrstrom and Director Fred Colen to retire from the Board at year-end after 8 years of service EINDHOVEN, the Netherlands, Oct. 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative...
- Anthony Dick
- Emira Sagaama
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2024
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
- Anthony Dick
- Emira Sagaama
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2024
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Sharad Kumar S.P
Holdings Report - September 2024 Exor Added To The KBC Securities Hold...
1M Performance - Absolute: During Sept'24 (1M period), the KBCS Holdings Universe posted a return of -0.2% which was mainly driven by multi-asset holdings (-1.2%) while single-asset holdings posted a positive return of 2.0%. The 3 top performers during the period were Sofina (+15.3%), Financière de Tubize (+8.4%), and Brederode (+7.2%) while the 3 worst performers were Exor (-4.4%), Compagnie du Bois Sauvage (-5.5%), and D'Ieteren Group (-7.2%). YTD Performance - Relative: On a YTD basis (as o...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
- Thomas Vranken
Onward Medical FIRST LOOK: Entering the BCI arena
Onward announced a license agreement with the French research institute CEA for exclusive rights to Clinatec's WIMAGINE BCI. Onward already collaborated with Clinatec for several years, and now brings the technology inhouse for further development. We see the move as a solid step forward given WIMAGINE's established safety profile, long-lasting signal stability and proven compatibility with Onward's ARC-IM technology. We reiterate our € 9.3 TP and Buy rating, as we look out for the anticipated F...
- Stefano Toffano
DSM-Firmenich : Q3 24 preview (31 October)
>Positive momentum continuing into Q3 24 - We expect continued momentum in DSM-Firmenich’s performance on the back of improving market developments and self-help initiatives. Q3 24 is another quarter with improving comps, and DSM-Firmenich should have been able to post another sequential quarter of positive yoy top-line growth. Easing end-markets pressures, stabilising (if not improving) destocking and pricing trends and continued focus on self-help initiatives should...
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clina...
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec’s WIMAGINE® Brain-Computer Interface (BCI) Technology THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ System WIMAGINE BCI has 7-year human safety data Deal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysis EINDHOVEN, the Netherlands, Oct. 15, 2024 (GLOBE NEWSWIRE)...
ONWARD® Medical signe un accord avec le CEA pour obtenir les droits ex...
ONWARD® Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d’interface cerveau machine (BCI) WIMAGINE® de Clinatec CE COMMUNIQUÉ DE PRESSE CONTIENT DES INFORMATIONS PRIVÉES AU SENS DE L'ARTICLE (7)(1) DU RÈGLEMENT EUROPÉEN SUR LES ABUS DE MARCHÉ (596/2014) L'entreprise obtient les droits exclusifs pour intégrer l’interface cerveau machine WIMAGINE dans son système ARC-BCI™ Le WIMAGINE BCI dispose de 7 ans de données de sécurité clinique sur des patients humains Cet accord offre à ONWARD Medical l'opportunité d'être le premier sur le marché avec un sy...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update October 2024 – Adding NN Group
We maintain a defensive stance on the market for 2H24. The long anticipated expectations for interest rate cuts by central banks will finally come to pass. The election fever in the US is reaching boiling point and the conversations are becoming more polarised than before. Also corporate profit growth in Europe slows and the French elections have cast a negative spell. In Germany by-elections in the Eastern part showed a shift to extreme right and left that will make budget decisions even more ...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
COFB COFINIMMO SA
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
KIN KINEPOLIS GROUP NV
NN NN GROUP N.V.
TINC TINC COMM. VA
FUR FUGRO NV
SYENS SYENSQO
- Guy Sips
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
Life Sciences Conference 26.09.2024
This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX
- Thomas Vranken
Onward Medical French listing and new ARC-BCI participant
Onward announced that it will start listing its shares on Euronext Paris in addition to Brussels and Amsterdam as of September 24. The listing is expected to provide greater access to French investors, but is non-dilutive to current shareholders. Furthermore, Onward recently announced a third study participant that was implanted with the ARC-BCI system. We reiterate our € 9.3 TP and Buy rating, as we look forward to the expected FDA approval of ARC-EX toward YE24.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.